Previous Close | 94.64 |
Open | 94.36 |
Bid | 0.00 x 900 |
Ask | 0.00 x 1100 |
Day's Range | 93.14 - 94.75 |
52 Week Range | 70.89 - 94.92 |
Volume | |
Avg. Volume | 11,374,059 |
Market Cap | 237.076B |
Beta (5Y Monthly) | 0.37 |
PE Ratio (TTM) | 16.78 |
EPS (TTM) | 5.59 |
Earnings Date | Jul 28, 2022 |
Forward Dividend & Yield | 2.76 (2.92%) |
Ex-Dividend Date | Jun 14, 2022 |
1y Target Est | 96.54 |
Pharma stocks Merck (NYSE: MRK) and Johnson & Johnson (NYSE: JNJ) have gained 23% and 5%, respectively, year to date. Merck had five blockbuster products in 2021, including the top-selling cancer drug in the world, Keytruda.
The European Commission approves Merck's (MRK) Keytruda for high-risk early-stage TNBC, which expands its eligible patient population.
RAHWAY, N.J., May 24, 2022--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.69 per share of the company’s common stock for the third quarter of 2022. Payment will be made on July 8, 2022 to shareholders of record at the close of business on June 15, 2022.